In Brief: Gonadotropin patent
Executive Summary
Gonadotropin patent: Ares-Serono and Organon settle long-standing infringement suit in the U.S. and the Netherlands. Organon will receive a non-exclusive worldwide license for manufacture and marketing of recombinant fertility hormones in exchange for upfront payments and royalties paid to Ares-Serono. Settlement "will allow the broadest possible use of genetically-engineered gonadotropins," Ares-Serono says...